News from novartis pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Nov 19, 2020, 10:12 ET New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Novartis announced today that new research data from a broad range of hematology medicines and investigational therapies will be presented at the...
Nov 13, 2020, 10:00 ET New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
Novartis today announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11 trials, evaluating the impact of age and gender...
Nov 05, 2020, 01:15 ET Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized...
Sep 11, 2020, 11:01 ET Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
Novartis announced today new post hoc data showing the efficacy and safety of Kesimpta® (ofatumumab), a targeted B-cell therapy, in patients with...
Aug 30, 2020, 02:30 ET Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Novartis today announced results from a post-hoc analysis of pooled data from the Phase III ORION-10 and -11 trials evaluating the individual...
Aug 20, 2020, 14:29 ET FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for...
Aug 13, 2020, 01:00 ET Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
Novartis today announced that the US Food and Drug Administration (FDA) accepted the company's supplemental Biologics License Application (sBLA) for...
Jun 16, 2020, 22:20 ET Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
Novartis, a leader in rheumatology and immuno-dermatology, today announced that the US Food and Drug Administration (FDA) has approved Cosentyx®...
Mar 28, 2020, 11:01 ET Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of...
Mar 18, 2020, 17:28 ET Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-class small interfering RNA...
Mar 18, 2020, 16:19 ET Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements
Novartis Pharmaceuticals Corporation (Novartis) announced a Consumer Product Safety Commission (CPSC)-approved corrective action plan after...
Feb 11, 2020, 01:18 ET Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Novartis announced today that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib's (INC280) New Drug...
Dec 11, 2019, 01:00 ET Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
The submission is based on positive results from the Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with nasal ...
Dec 09, 2019, 14:50 ET Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Novartis today announced results from two analyses of real-world experience with Kymriah® (tisagenlecleucel), the only CAR-T cell therapy approved in ...
Nov 17, 2019, 10:45 ET Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1...
Nov 15, 2019, 16:32 ET New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo® (crizanlizumab-tmca), previously known as SEG101, to reduce ...
Oct 08, 2019, 07:15 ET Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Novartis today announced that the U.S. Food and Drug Administration (FDA) approved BEOVU® (brolucizumab-dbll) injection, also known as RTH258, for...
Oct 02, 2019, 01:20 ET Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
Novartis, a leader in rheumatology and immuno-dermatology, today announced additional positive data from the PREVENT trial, evaluating the efficacy...
Sep 02, 2019, 02:32 ET Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of...
Jul 22, 2019, 07:30 ET Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home
Novartis is teaming up with celebrity interior designer Nate Berkus to launch My Home in Sight, a program that aims to raise awareness of the daily...
Jul 16, 2019, 01:23 ET FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
Novartis today announced the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) and has granted...
Jun 04, 2019, 13:03 ET Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
Novartis announced today results from the landmark COMBI-d and COMBI-v clinical trials, concluding that first-line treatment with Tafinlar...
Jun 03, 2019, 01:19 ET Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Novartis announced today new data and clinical trial updates in NSCLC at the ASCO 2019 Annual Meeting. This includes primary efficacy results from...
Jun 01, 2019, 07:35 ET Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Novartis today announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy1. The Phase 3...
May 24, 2019, 16:51 ET FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant...
